DiagnoCure to host Q1 2013 earnings conference call and webcast
QUEBEC CITY, Feb. 28, 2013 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) announced today that it will release its first quarter 2013 results on March 11, 2013, at 4:00 p.m. (EDT). DiagnoCure's management will host a conference call the same day, at 4:30 p.m. (EDT). Interested participants may listen to the call by dialing 1-888-231-8191 or 514-807-9895 and referencing code 11472852 approximately 15 minutes prior to the call. The Corporation will also provide a live webcast of the call. Interested participants may access the webcast on DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations. A replay of the webcast will be available on DiagnoCure's website for those unable to participate in the live webcast.
Annual and Special Meeting of Shareholders
DiagnoCure confirms that the Annual and Special Meeting of its shareholders will be held as follows:
|TIME:||Monday, April 29, 2013||LOCATION:||McCarthy Tétrault's offices|
|3:00 p.m. (EDT)||1000 de la Gauchetière Street West|
|Montréal (Québec) H3B 0A2|
On this occasion, Dr. Yves Fradet, President and Chief Medical Officer, and Chantal Miklosi, Chief Financial Officer will review the financial highlights and performance of the Corporation for the fiscal year ended October 31, 2012.
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation had launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE: DiagnoCure inc.For further information:
Chief Financial Officer
Coordinator, Administration and Communications